Revvity presents cutting-edge solutions at SLAS2024
Showcase will include more than 40 products from its life sciences and diagnostics protfolio
3 Feb 2024
Revvity, Inc. will display more than 40 products from its life sciences and diagnostics portfolio at SLAS2024 International Conference and Exhibition. The latest product introductions and technological synergies across its portfolio, which are designed to spur scientific advancement and drive efficiencies in drug development – with a special emphasis on the innovation and discovery phase – will be featured throughout its exhibit and in several talks and poster presentations.
New modalities: Technologies and services to design, deliver, and analyze genetic payloads helping to expand the frontiers of research, include: Pin-point™ base editing, AAV engineering and optimization +AAV process development services, LentiBOOST® GMP-grade transduction enhancer and a range of gene modification technologies. Also on display is the Revvity's newly launched LabChip® AAV empty/full characterization solution for gene therapy applications, adding to its genomics and proteomics analysis capabilities. This AAV assay offers important ease of use and throughput advantages over traditional AAV analysis methods.
Automation technologies: Integrated robotics and software solutions for increased productivity that include systems such as: chemagic™ 360 nucleic acid extraction system, Explorer™ G3 workstation with integrated Fontus™ liquid handler, FlexDrop™ iQ™ non-contact dispenser, and Omni™ LH 96 automated homogenization workstation.
Cellular technologies: Advanced technologies for cell analysis, which can enable research and discovery breakthroughs include: Cellaca® PLX image cytometry system, Opera Phenix® HCS system, Signals Image Artist™ software, CRISPR and RNAi reagents, cell painting assays, and the extensive range of BioLegend® antibodies for flow cytometry.
Omics: Comprehensive platforms for accelerated multiomic discoveries that include: Single cell proteogenomic assays and Omni™ Bead Ruptor™ solution for tissue homogenization.
Precision medicine and diagnostics: Tailored diagnostic-enabling and discovery technologies for improved patient outcomes include: BioLegend® reagents for flow cytometric cell phenotyping, BioQule™ NGS system for automated sample in-library out preparation, CDX assay development services, ELISPOT® secreted protein detection assays including the T-SPOT® latent TB screening test, and MojoSort™ magnetic cell separation system.
Assay development: Advanced solutions designed to increase throughput and precision of assays are in the spotlight and include: Dharmacon® reagents, including CRISPR/RNAi screening libraries, as well as services spanning functional genomics, cell panel and immune cell screening, and CRISPR-based cell line engineering. Revvity’s no-wash immunoassays and its detection and cellular imaging portfolios will be on display, including Revvity’s EnVision® Nexus™ Multimode microplate reader and IVIS® and Vega® in vivo imaging platforms.